Giant Biogene Holding Co., Ltd. (HKG:2367) last week reported its latest interim results, which makes it a good time for investors to dive in and see if the business is performing in line with expectations. Giant Biogene Holding reported in line with analyst predictions, delivering revenues of CN¥2.9b and statutory earnings per share of CN¥1.85, suggesting the business is executing well and in line with its plan. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.
Taking into account the latest results, the consensus forecast from Giant Biogene Holding's 17 analysts is for revenues of CN¥6.05b in 2026. This reflects a notable 14% improvement in revenue compared to the last 12 months. Statutory earnings per share are predicted to swell 15% to CN¥1.81. Before this earnings report, the analysts had been forecasting revenues of CN¥6.12b and earnings per share (EPS) of CN¥1.79 in 2026. The consensus analysts don't seem to have seen anything in these results that would have changed their view on the business, given there's been no major change to their estimates.
See our latest analysis for Giant Biogene Holding
The analysts reconfirmed their price target of HK$39.88, showing that the business is executing well and in line with expectations. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. Currently, the most bullish analyst values Giant Biogene Holding at HK$82.20 per share, while the most bearish prices it at HK$25.00. With such a wide range in price targets, analysts are almost certainly betting on widely divergent outcomes in the underlying business. With this in mind, we wouldn't rely too heavily the consensus price target, as it is just an average and analysts clearly have some deeply divergent views on the business.
These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Giant Biogene Holding's past performance and to peers in the same industry. The analysts are definitely expecting Giant Biogene Holding's growth to accelerate, with the forecast 29% annualised growth to the end of 2026 ranking favourably alongside historical growth of 19% per annum over the past three years. Compare this with other companies in the same industry, which are forecast to grow their revenue 14% annually. It seems obvious that, while the growth outlook is brighter than the recent past, the analysts also expect Giant Biogene Holding to grow faster than the wider industry.
The Bottom Line
The most obvious conclusion is that there's been no major change in the business' prospects in recent times, with the analysts holding their earnings forecasts steady, in line with previous estimates. Happily, there were no major changes to revenue forecasts, with the business still expected to grow faster than the wider industry. The consensus price target held steady at HK$39.88, with the latest estimates not enough to have an impact on their price targets.
Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. At Simply Wall St, we have a full range of analyst estimates for Giant Biogene Holding going out to 2028, and you can see them free on our platform here..
Don't forget that there may still be risks. For instance, we've identified 1 warning sign for Giant Biogene Holding that you should be aware of.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.